Extending breast cancer screening to younger women will benefit in terms of economic efficiency and equity

Screening younger women for breast cancer is fairer and makes sound economic sense, according to new research by the University of East Anglia (UEA).

Published online today by the leading journal Value in Health, the study assessed the current screening guidelines in terms of both cost effectiveness and fairness.

The researchers concluded that extending the hotly-debated screening programme to younger women would have real benefits in terms of both economic efficiency and equity. The approach could also be used for other fatal diseases with similar age distributions.

"Screening only older women increases unfair disparities in terms of life expectancy, quality of life and incidence of disease," said principal investigator Prof Louis Niessen, a public health economist at UEA's School of Medicine.

"Our findings show that extending screening to younger women will lead to a better mix of health programmes and a more balanced approach to the fight against breast cancer."

Prof Niessen urged policymakers and agencies such as NICE to use proper value-based weighing methods and take women's preferences into account when next reviewing breast cancer control guidelines.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy